Search

Maravai LifeSciences Holdings Inc (Class A)

Suletud

SektorTervishoid

8.4 -2.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.11

Max

8.61

Põhinäitajad

By Trading Economics

Sissetulek

-21M

-24M

Müük

-14M

51M

Aktsiakasum

-0.07

Kasumimarginaal

-47.189

Töötajad

415

EBITDA

-17M

-5.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-16.09% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-265M

2.1B

Eelmine avamishind

10.84

Eelmine sulgemishind

8.4

Uudiste sentiment

By Acuity

100%

0%

326 / 340 Pingereas Healthcare

Maravai LifeSciences Holdings Inc (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 20:06 UTC

Maravai LifeSciences is declining amid broader market pressures from rising oil prices and geopolitical tensions, despite reaching a session high earlier.

21. aug 2026, 19:43 UTC

Maravai LifeSciences Holdings Inc is trading higher today, supported by increased investor interest and unusually high trading volume, despite no specific news identified.

20. aug 2026, 23:11 UTC

Maravai LifeSciences Holdings Inc. shares are trading roughly flat in after-market hours amid mixed market sentiment influenced by recent fluctuations in U.S. Treasury yields.

19. aug 2026, 23:11 UTC

Maravai LifeSciences Holdings Inc. shares are higher in after-market trading, recovering from an initial dip despite no specific news to explain the movement.

18. aug 2026, 19:56 UTC

Maravai LifeSciences is trading higher today, recovering from earlier lows, despite broader market pressures and rising Treasury yields amid inflation concerns.

17. aug 2026, 20:06 UTC

Maravai LifeSciences Holdings Inc is lower today, continuing a decline since Friday. Shares are near the lower end of their one-month range.

14. aug 2026, 19:16 UTC

Maravai LifeSciences Holdings Inc. shares are lower, retracing from earlier gains amid broader market concerns over a decline in U.S. retail sales.

11. aug 2026, 20:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, continuing a trend of five consecutive daily declines and trading below the 20-day moving average.

10. aug 2026, 19:46 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, but shares are trading lower amid mixed analyst ratings and a continuing decline since Friday.

7. aug 2026, 20:02 UTC

News

Maravai LifeSciences shares are lower despite Wells Fargo raising the price target to $6.50 following a revenue increase to $51.4 million in Q2.

6. aug 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

3. aug 2026, 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31. juuli 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30. juuli 2026, 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29. juuli 2026, 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28. juuli 2026, 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24. juuli 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23. juuli 2026, 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22. juuli 2026, 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21. juuli 2026, 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20. juuli 2026, 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Võrdlus sarnastega

Hinnamuutus

Maravai LifeSciences Holdings Inc (Class A) Prognoos

Hinnasiht

By TipRanks

-16.09% langus

12 kuu keskmine prognoos

Keskmine 7.25 USD  -16.09%

Kõrge 8 USD

Madal 6.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

326 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat